Article
Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease.
BMC pharmacology & toxicology - 8 Apr 2017
Xu Yuanyuan, Wang Yan, Zhi Jixin, Qi Lichun, Zhang Tong, Li Xueqi
Abstract excerpt
BACKGROUND: Genetic variation of matrix metalloproteinase 9 (MMP-9) gene polymorphism has been suggested to modulate coronary heart diseases (CHD), yet the underlying mechanisms are not well understood. METHODS: We investigated the association of MMP9 rs3918242 single nucleotide polymorphism with inflammation and lipid-lowering efficacy after simvastatin treatment in Chinese patients with CHD. Fasting serum lipid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
